JXTG Holdings

History

2018: Sale of biotechnology divisions for $800 million

At the end of March, 2018 the Japanese producer photo and Fujifilm Holdings medical equipment announced purchase of two biotechnology divisions of JXTG Holdings company for the purpose of strengthening of the positions in the market of health care.

Fujifilm purchases at JXTG Holdings of Irvine Scientific company (it is founded in 1987) and IS Japan (1989) for $800 million. Both "subsidiaries" of the Japanese holding are engaged in development of nutrient medium for cultivation of cultures of cages for the biopharmaceutical and medical markets and also the market of cellular therapy.

Fujifilm purchased two biotechnology divisions of the oil and gas company, largest in Japan, for $800 million

After extraction of cages from fabric or an organism and the premises them in culture the cultural environment should provide all external conditions which cages had in vivo. It provides survival of cages, their proliferation and a differentiation. The extracellular environment should provide cages with nutritious and hormonal factors, i.e. have all necessary for growth and survival of cages.

Though this business of JXTG shows strong growth, the medical equipment and medicobiological sciences are not synergy for key business of the company in the future, said in the press release of JXTG. Fujifilm reported the following:

For promotion of the growth strategies in the field of health care Fujifilm continues to invest in contract development and production of biopharmaceutical medicines and regenerative medicine.

The company expects that the market connected with cultural environments will show annual growth not less than for 10%. In 2016 Fujifilm already purchased the company from this area — Wako Pure Chemical Industries.

After merger of Irvine Scientific and IS Japan the Japanese company will be able to offer still a wide range of products — from biopharmaceutical medicines to solutions in the field of extracorporal fertilization and cellular therapy that will allow to strengthen global Fujifilm Diosynth Biotechnologies business divisions.^[1]

Notes